Physician profile
Ruel Taylor
NPI 1285703058
$522.27
in general payments reported to CMS, 2019-2025
8 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $457 · 2020: $65.69.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $282.63 | 2019-2020 | |
| Janssen Biotech, INC. | $109.61 | 2019 | |
| Boston Scientific Corporation | $36.21 | 2019 | |
| Bioventus LLC | $24.46 | 2019 | |
| Endo Pharmaceuticals INC. | $18.90 | 2019 | |
| Amgen INC. | $17.18 | 2019 | |
| Medtronic USA, INC. | $16.65 | 2019 | |
| Neotract INC. | $16.63 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ruel Taylor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.